Shopping Cart

Your shopping cart is currently empty

Varespladib sodium

Name: Varespladib sodium
Brand: TargetMol
SKU: T39173
Price: 69 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: LY315920 sodium) Copy Product Info

🥰Excellent

Synonyms: LY315920 sodium

Catalog No. T39173 Copy Product Info

🥰Excellent

Varespladib sodium is a potent and selective inhibitor of secretory phospholipase A2 (sPLA2), with an IC50 of approximately 9 nM against group IIA sPLA2. It exhibits nanomolar inhibitory activity in serum from various species, including rat, rabbit, guinea pig, and human. It is commonly used in research related to inflammation and lipid metabolism.

Cas No. 172733-42-5

Pack Size	Price	USA Stock	Global Stock	Quantity
1 mg	$69	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Varespladib sodium is a potent and selective inhibitor of secretory phospholipase A2 (sPLA2), with an IC50 of approximately 9 nM against group IIA sPLA2. It exhibits nanomolar inhibitory activity in serum from various species, including rat, rabbit, guinea pig, and human. It is commonly used in research related to inflammation and lipid metabolism.
Targets & IC50	sPLA2:9 nM
In vitro	Varespladib sodium (10 μM; 24 and 48 hours; HCjE cells) treatment Results: in complete inhibition of the RA-induced increase in MUC16 protein detected in cell lysates at both time points. Varespladib sodium (10 μM; 24 and 48 hours; HCjE cells) treatment significantly inhibits RA-induced MUC16 expression by 100% at 24 hours and 99% at 48 hours. Varespladib sodium at 10 μM significantly inhibited RA-induced MUC16 expression in HCjE cells at both 24 h and 48 h, as demonstrated by Western blot and RT-PCR analyses (100% inhibition at 24 h and 99% at 48 h)[2].
In vivo	Varespladib sodium treatment inhibits human sPLA 2 -induced release of thromboxane A 2 (TXA 2 ) from isolated guinea pig lung bronchoalveolar lavage cells with an IC 50 of 0.79 μM. And the ED 50 for Varespladib sodium is 16.1 mg/kg. Varespladib sodium, administered intravenously at 3, 10, and 30 mg/kg in male Hartley guinea pigs (300–500 g), consistently inhibited sPLA₂ activity in bronchoalveolar lavage fluid and reduced human sPLA₂-induced TXA₂ generation in BAL cells[1].
Synonyms	LY315920 sodium

Chemical Properties

Molecular Weight	402.38
Formula	C₂₁H₁₉N₂NaO₅
Cas No.	172733-42-5
Smiles	O=C(C(C1=C(CC)N(CC2=CC=CC=C2)C3=C1C(OCC([O-])=O)=CC=C3)=O)N.[Na+]

Storage & Solubility Information

Storage

Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 10 mg/mL (24.85 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4852 mL	12.4261 mL	24.8521 mL	124.2606 mL
5 mM	0.4970 mL	2.4852 mL	4.9704 mL	24.8521 mL
10 mM	0.2485 mL	1.2426 mL	2.4852 mL	12.4261 mL
20 mM	0.1243 mL	0.6213 mL	1.2426 mL	6.2130 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Keywords

Varespladib sodium

Related Tags: Varespladib sodium chemical structure | Varespladib sodium in vivo | Varespladib sodium in vitro | Varespladib sodium formula | Varespladib sodium molecular weight